STL Index for: Pimecrolimus
Mild to moderate atopic dermatitis (AD) is often controlled by behavioral measures such as skincare and avoidance of triggers in addition to topical treatments such as topical corticosteroids (TCS), topical calcineurin inhibitors (TCI), and crisaborole, a phosphodiesterase-4 inhibitor (PDE4-I).
Crisaborole provides a novel and safe treatment option for mild-to-moderate AD.
Topical calcineurin inhibitors (TCIs) have been proposed as an alternative, long-term treatment option to topical corticosteroids. Currently, TCIs are only approved for treatment of atopic dermatitis in patients 2 years of age or older. This article reviews the off-label uses of TCIs and their efficacy in the treatment of cutaneous diseases.
This article reviews topical corticosteroids (TCS) and topical calcineurin inhibitors (TCIs) to manage inflammatory conditions, its risks with long-term use, and the role of moisturizing as important therapeutic adjuncts.
Rosacea is a common chronic skin disorder that has significant impact on the quality of life of affected individuals. Research interest has led to the development of other emerging therapies including topical ivermectin, brimonidine and oxymetazoline that hold promise for patients suffering from this condition.
This article discusses atopic dermatitis, its pathogenesis, and general treatment principles as well as specific therapeutic options.
This paper examines the pathogenesis of atopic dermatitis, the skin barrier, and the role that ceramides can play in therapy.
Hand eczema affects up to 10% of the population and encompasses a diverse range of morphological presentations and underlying pathophysiological processes. This article will review the new and existing treatments that are available for this common dermatologic problem.
Many options exist for the treatment of rosacea, including topical and systemic therapies, laser and light-based therapies, and surgical procedures. The goals of therapy include reduction of papules, pustules, erythema, physical discomfort, and an improvement in quality of life.
Psoriasis represents a potentially life-altering disease that can profoundly impact physical, emotional and social functioning, and overall quality of life. Part I of this 2-part series will focus on topical agents, their varying degrees of effectiveness, potential side-effects and applications in clinical practice.
TCIs have an important place in the therapeutic armamentarium for AD. They are approved as second line agents for individuals >2 years of age, and have a good safety profile when used short-term or intermittently long-term.
Elidel (Pimecrolimus) is indicated for patients with mild to moderate atopic dermatitis. This article discusses patient profiles, and use in a variety of dermatological conditions.
Elidel (Pimecrolimus) is discussed in the context of dosing, efficacy, compliance, and cost of treatment are discussed.
Elidel (Pimecrolimus), its side effects, safety, and risks are discussed in this article. Various potential risks are discussed and debated.
The prevalence of eczema is increasing over the past 30 years, and is estimated to affect 20% of children in North America and Northern Europe. This article discusses eczema, incidence, clinical presentations, and management, as well as specific primary and second line therapies.
Although the developing fetus was once considered protected from the outside world, we now know that it can potentially be affected by any medication given to the mother. Therapeutic options available for these patients will be discussed.
Atopic dermatitis is a highly pruritic inflammatory disorder of the skin characterized by onset in infancy or childhood and a chronically relapsing course. Mainstay treatments are emollients and topical corticosteroids, but the latter are limited by side-effects from longterm use.
In February of this year, the US FDA issued a public health advisory to inform healthcare providers and patients about a potential cancer risk from the topical use of pimecrolimus (Elidel©, Novartis), approved by the FDA in December 2001, and tacrolimus (Protopic©, Astellas, formerly Fujisawa), approved in December 2000.
Tacrolimus ointment (Protopic®, Fujisawa) is an effective agent in a class of topical immunomodulators. It has been shown to be safe and effective in adults and children with Atopic Dermatitis in short- and long-term treatments.
Allergic contact dermatitis (ACD) may account for at least 20% of all childhood dermatitis. Clinically, its morphology is identical to other forms of dermatitis in acute, subacute and chronic forms. A persistent or unusual and localized pattern is often the key to diagnosis.
Pimecrolimus is an immunomodulating medication that inhibits production of inflammatory cytokines in the skin and this compound was specifically developed for the treatment of inflammatory skin diseases.